论文部分内容阅读
目的探讨免疫组化检查(IHC)对乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)、C-erbB-2表达与乳腺癌临床治疗及预后判断的意义。方法收集本院88例乳腺癌临床病理学资料,进行常规HE切片及ER、PR检查,采用Elivision法分别测定88例乳腺癌组织ER、PR、C-erbB-2的表达,有条件的病例作FISH检测,并与FISH进行比较;同时评估IHC对乳腺癌ER、PR、C-erbB-2表达情况,复习相关文献资料,研究乳腺癌ER、PR及HER2等检测与临床预后意义。结果在88例乳腺癌中病免疫病理检查结果显示:ER约60%呈阳性反应,c-erbB-2约26%阳性。结论结合免疫组化表达进行综合分析,对提高乳腺癌的诊断及预后判断,指导临床治疗方案有明显的临床意义。
Objective To investigate the significance of immunohistochemistry (IHC) on the expression of estrogen receptor (ER), progesterone receptor (PR) and C-erbB-2 in breast cancer and the clinical treatment and prognosis of breast cancer. Methods The clinicopathological data of 88 cases of breast cancer in our hospital were collected. The routine HE sections and ER, PR were examined. The expression of ER, PR and C-erbB-2 in 88 cases of breast cancer were detected by Elivision method. The conditional cases FISH, and compared with FISH. We also evaluated IHC expression of ER, PR and C-erbB-2 in breast cancer and reviewed related literatures to study the clinical significance of ER, PR and HER2 in breast cancer. Results Immunohistopathological examination of 88 cases of breast cancer showed that about 60% of ER was positive and about 26% of c-erbB-2 was positive. Conclusions Combined with immunohistochemical analysis, it has obvious clinical significance to improve the diagnosis and prognosis of breast cancer and guide the clinical treatment.